Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 2/2010

01-11-2010 | Review

Intervention in at-risk states for developing psychosis

Authors: Stephan Ruhrmann, Frauke Schultze-Lutter, Andreas Bechdolf, Joachim Klosterkötter

Published in: European Archives of Psychiatry and Clinical Neuroscience | Special Issue 2/2010

Login to get access

Abstract

Indicated prevention is currently one of the most promising approaches to fight the individual and societal burden associated with psychosis and particularly schizophrenia. The number of studies is still limited, yet encouraging results have been reported from pharmacological and psychotherapeutic trials. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention but also treatment. As is indicated by a recent study successfully using omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. An overview on the current findings and ongoing research in this area is provided.
Literature
1.
Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154CrossRefPubMed
2.
3.
Bechdolf A, Ruhrmann S, Wagner M et al (2005) Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry Suppl 48:s45–s48CrossRef
4.
Bechdolf A, Veith V, Vogeley K et al (2008) PREVENT: background and rational of a clinical study comparing the preventive effects of CBT, aripriprazole and placebo in persons at-risk for psychosis. Early Interv Psychiatry 2(Suppl 1):11
5.
Berger G, Wood S, Ross M et al (2008) Neuroprotective effects of low dose lithium in individuals at ultra-high risk for psychosis. Early Interv Psychiatry 2:A28
6.
Cornblatt BA, Lencz T, Smith CW et al (2007) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 68:546–557CrossRefPubMed
7.
Fusar-Poli P, Valmaggia L, McGuire P (2007) Can antidepressants prevent psychosis? Lancet 370:1746–1748CrossRefPubMed
8.
Häfner H, an der Heiden W (2008) Course and Outcome. In: Mueser KT, Jeste DV (eds) Clinical handbook of schizophrenia. The Guilford Press, New York, NY, pp 100–113
9.
Haynes RB, Sackett DL, Guyatt GH et al (2006) Clinical epidemiology. Lippincott Williams & Williams, Philadelphia
10.
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276PubMed
11.
Klosterkötter J (2008) Indicated prevention of schizophrenia. Dtsch Arztebl Int 105:532–539PubMed
12.
Klosterkötter J, Hellmich M, Steinmeyer EM et al (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiat 58:158–164CrossRefPubMed
13.
Kuipers E, Bebbington P (2006) Cognitive behaviour therapy for psychosis. Epidemiol Psichiatr Soc 15:267–275PubMed
14.
Kumra S, Oberstar JV, Sikich L et al (2008) Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34:60–71CrossRefPubMed
15.
McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiat 163:790–799CrossRefPubMed
16.
McGorry PD, Hickie IB, Yung AR et al (2006) Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 40:616–622PubMed
17.
McGorry PD, Nelson B, Amminger GP et al (2009) Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 70:1206–1212CrossRefPubMed
18.
McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiat 59:921–928CrossRefPubMed
19.
Moreno C, Arango C, Parellada M et al (2007) Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiat Scand 115:184–195CrossRefPubMed
20.
Morrison AP, French P, Bentall RP et al (2008) Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Interv Psychiatry 2:A15
21.
Morrison AP, French P, Parker S et al (2007) Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 33:682–687CrossRefPubMed
22.
Morrison AP, French P, Walford L et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Brit J Psychiat 185:291–297CrossRefPubMed
23.
Nuechterlein KH (1987) Vulnerability models for schizophrenia: State of the art. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia. Springer, Heidelberg, pp 297–316
24.
O’Brien MP, Zinberg JL, Bearden CE et al (2007) Psychoeducational multi-family group treatment with adolescents at high risk for developing psychosis. Early Interv Psychiatry 1:325–332CrossRef
25.
O’Brien MP, Zinberg JL, Ho L et al (2009) Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: a longitudinal study. Schizophr Res 107:198–205CrossRefPubMed
26.
Papakostas GI (2008) Tolerability of modern antidepressants. J Clin Psychiatry 69(Suppl E1):8–13PubMed
27.
Phillips LJ, McGorry PD, Yuen HP et al (2007) Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 96:25–33CrossRefPubMed
28.
Phillips LJ, Nelson B, Yuen HP et al (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiat 43:818–829CrossRef
29.
Rietdijk J, Dragt S, Klaassen R et al (2010) A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials 11
30.
Ruhrmann S, Bechdolf A, Kuhn KU et al (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51:S88–S95CrossRefPubMed
31.
Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2010) Probably at-risk, but certainly ill—Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 120:23–37
32.
Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl 3):S162–S167PubMed
33.
Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251CrossRefPubMed
34.
Schultze-Lutter F, Ruhrmann S, Berning J et al (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 36:182–191CrossRefPubMed
35.
Schultze-Lutter F, Ruhrmann S, Klosterkötter J (2006) Can schizophrenia be predicted phenomenologically? In: Johannesen JO, Martindale BV, Cullberg J (eds) Evolving psychosis: different stages, different treatments. Routledge, Hove, pp 104–123
36.
Simon AE, Dvorsky DN, Boesch J et al (2006) Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res 81:83–90CrossRefPubMed
37.
Svirskis T, Korkeila J, Heinimaa M et al (2005) Axis-I disorders and vulnerability to psychosis. Schizophr Res 75:439–446CrossRefPubMed
38.
HO W (2004) Prevention of mental disorders : effective interventions and policy options. World Helath Organization, Geneva
39.
Wood SJ, Berger GE, Dell’Olio M et al (2007) Effects of low dose lithium on hippocampal neuropathology in people at ultra-high risk for psychosis. Biol Psychiat 61:259s–260s
40.
Woods SW, Breier A, Zipursky RB et al (2003) Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiat 54:453–464CrossRefPubMed
41.
Woods SW, Tully EM, Walsh BC et al (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:s96–s101CrossRefPubMed
42.
Woods SW, Walsh B, Pearlson GD et al (2006) Glycine treatment of prodromal symptoms. Schizophr Res 86(Suppl):S7
Metadata
Title
Intervention in at-risk states for developing psychosis
Authors
Stephan Ruhrmann
Frauke Schultze-Lutter
Andreas Bechdolf
Joachim Klosterkötter
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue Special Issue 2/2010
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-010-0139-5

Other articles of this Special Issue 2/2010

European Archives of Psychiatry and Clinical Neuroscience 2/2010 Go to the issue

Review

Individualised treatment in alcohol-dependent patients

Original Paper

Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia

Original Paper

Cognitive performance and cholinergic transmission: influence of muscarinic and nicotinic receptor blockade

Review

Is there a personalized medicine for mood disorders?

Editorial

Psychiatric illness through the lifespan

Original Paper

Social reinforcement can regulate localized brain activity